Cytosorbents Corp — Director's Dealing 2013

Feb 14, 2013

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Cytosorbents Corp (CTSO)
CIK: 0001175151
Period of Report: 2012-12-31

Reporting Person: Rubin Joseph (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-10-05	Series B Convertible Preferred	$0.0362	C	36.20	Acquired		Common Stock, par value $0.001 per share (100000)	Direct

Footnotes

F1: Immediately exercisable

F2: Not Applicable

F3: This amount includes all shares of Series B Convertible Preferred stock issued as quarterly dividend shares. The Series B Convertible Preferred Stock pays dividends quarterly at a rate of 10% per annum. If fully converted, they would be convertible into 562,265 shares of Common Stock